When off-label may mean off-target: How would doctors and insurers navigate demand for a new, narrow Alzheimer’s drug?

October 13, 2020
STAT News

Related news

In the news

April 18, 2024

Dr. YuQian Liu Investigates the Future Benefits of Cell, Gene Therapies Using Real-World Data

American Journal of Managed Care (AJMC): YuQian Liu, PharmD, Magellan Rx Management, explores the current space of cell and gene therapies based on real-world data and potential emerging therapies in the future, while expanding upon long-term efficacy concerns.

In the news

April 18, 2024

Multiple Sclerosis Generics Switching Program Saves Millions

Specialty Pharmacy Continuum: A program in which managed care pharmacists reached out to healthcare providers in 2023 to advise them of potential cost savings that could accrue by switching their patients with multiple sclerosis (MS) from branded to generic therapies has generated significant savings

In the news

April 16, 2024

Prime Study Finds Lower Adherence, Higher Costs for Weight Loss Drugs | AMCP 2024

Managed Healthcare Executive: Use of GLP-1 drugs and weight-loss care management programs need to focus on adherence and persistency for better health outcomes, suggests Prime Therapeutics/MagellanRx Management poster at AMCP 2024